One of the coolest findings I’ve seen in human brain imaging.
When @immanuel_elbau first showed me that ECT changed hippocampal connectivity in our densely-sampled patient (39 study visits over 6 months), I expected a familiar default mode network (DMN) pattern, just stronger or weaker.
@chrisaikenmd Thanks for flagging this, Chris. As you note, this framework hasn't been independently validated. Heterogeneity is real, but we still lack a validated way to subtype depression that informs treatment. Solving that is one of the most important research challenges in our field.
Recent TMS trials have shown that fMRI-guided TMS can outperform conventional scalp-based targeting for depression.
In our new Brain Stimulation commentary, we explore some of the exciting questions these advances open up.
https://t.co/dE1Xpb26cO
Thank you to all the Veterans who came out today for a conversation about #depression, its treatment, and research into its causes and new treatments at MIRECC and VA. @VeteransHealth
A day after Veterans Day, I'm honored to join Veterans at the Bronx VA this morning for a conversation about depression: how it's treated and where research is headed. Grateful to the MIRECC team and to all who served. 🇺🇸 @VABronx@VeteransHealth https://t.co/PRQmr8SS2x
A day after Veterans Day, I'm honored to join Veterans at the Bronx VA this morning for a conversation about depression: how it's treated and where research is headed. Grateful to the MIRECC team and to all who served. 🇺🇸 @VABronx@VeteransHealth https://t.co/PRQmr8SS2x
You’re invited!
A Talk for Veterans: A Conversation About Depression.
Join Dr. James Murrough, MD, PhD, for an open conversation about depression, followed by time for questions and connection. Meet the MIRECC team and enjoy coffee and snacks.
The Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai is proud to be part of an institution recognized for excellence, ranking No. 1 in New York State and No. 9 nationally in NIH research funding.
Read more: https://t.co/smZq0faW3q
I am incredibly proud of @IcahnMountSinai's faculty and trainees whose cutting-edge, impactful research brought Mount Sinai into the top 10 of NIH-funded institutions for the first time in FY26.
Nice commentary on a key issue in psychiatric and medical clinical trial design. Functional unblinding and expectancy are not unique to psychedelics, but psychedelic-like drugs are particularly vulnerable to them.
A commentary published in JCP argues that blinding integrity is rarely assessed in trials of drugs with noticeable effects, citing a review in which only 30% of 112 psychedelic and ketamine trials assessed it, and recommends asking patients what they guessed, why, and when. JCP → https://t.co/Z157RBDxJ3
#ClinicalTrials #Psychopharmacology #JCP
@RecoveryDoctor@ASCPorg 100% agree, Michael. Expert consensus is no substitute for clinical trials. At best, it draws on existing trial evidence plus clinicians' experience, but more trials are always better. The caveat is that we will likely never have a clinical trial for every clinical question.
An ASCP task force of 60 experts from 16 countries, publishing in JCP, reached consensus on 62 of 66 items about combination psychopharmacology, concluding that a regimen’s mechanistic coherence matters more than the number of medications it includes. JCP → https://t.co/zQiidYlG7c
#Psychopharmacology #Psychiatry #JCP
Artificial intelligence is becoming part of everyday clinical practice—and increasingly, part of our patients' lives.
ADAA Member @JohnTorousMD explores how clinicians can have informed, thoughtful conversations about AI chatbot use in therapy.
https://t.co/UBdMBySmtN
What if a depression treatment worked in hours, not weeks? I joined Dennis Charney and Adriana Feder for @MountSinaiNYC's Vitals on how ketamine went from anesthetic to rapid-acting treatment for depression. @IcahnMountSinai@MountSinaiPsych@SinaiBrain https://t.co/1kl1zzShRd
Very timely article! I sometimes wonder: do any of my patients not engage with apps or other digital technology in their journey to relieve suffering and enhance wellness?
Wellness app or digital therapeutic? Your patients may not know the difference, but your treatment plan should.
Dr. Sagar Parikh (University of Michigan) walks through a new consensus panel paper in The Journal of Clinical Psychiatry that covers:
→ What separates a digital therapeutic from a wellness app
→ Four consensus statements to guide use in everyday practice
→ Where digital therapeutics fit within stepped care for MDD
→ Practical guidance for bringing these tools into your clinic
Read the full consensus report: https://t.co/YD1csuPl5T
#Psychiatry #Depression #MDD #DigitalTherapeutics #DigitalHealth #MentalHealth
Dr. Frederick Barrett (@FredBarrettPhD) remarks in an article with the New York Times on the potential of novel treatments such as psychedelics for brain diseases like CTE (Chronic Traumatic Encephalopathy). https://t.co/ROG72nvm4Q
On @MountSinaiNYC's The Vitals, I joined Veerle Bergink and Shilpa Taufique for a conversation about the state of mental health. Even as treatments improve, many people who need care still cannot get it. We also talked about stigma and what's changing in how we understand and treat depression and other psychiatric illnesses. Important discussion! https://t.co/hwLgSaufTJ
Older adults with mild cognitive impairment are often left out of ketamine trials. In this open-label pilot of 13 people, one infusion was tolerated and depression scores fell sharply at 24 hours, with gains lasting a month for some. The Mount Sinai team flags the need for a real randomized trial.
Dr. David Yaden spoke on a panel that brought together scientific, policy, and legal perspectives on psychedelic treatment at Yale Law School’s Solomon Center for Health Law and Policy, reviewing what the science can and cannot yet tell us, including how to weigh their risks and benefits. https://t.co/mAfsI2tYG5